Effects of long-term administration of melatonin and a putative antagonist on the ageing rat

Bondy

Neurochemistry International

et al. 2007

The expression levels of a number of genes associated with inflammation and immune function change with advancing age. Melatonin modulates gene expression levels of several of these genes. Therefore the declining levels of melatonin associated with age may play a role in the physiological effects of aging. We used oligonucleotide microarrays to measure age-related changes in mRNA expression in the murine CNS, and to study the effect of prolonged administration of dietary melatonin upon these changes. CB6F1 male mice were fed 40ppm melatonin for 2.1 months prior to sacrifice at age 26.5 months, and compared with both age-matched controls and young, 4.5-monthold untreated controls. Total RNA was extracted from whole brain (excluding cerebellum and brain stem) and individual samples were hybridized to Affymetrix Mouse 430-2.0 arrays. The expression of a substantial number of genes was modulated by melatonin treatment and changes in selected genes were validated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). A subset of these genes did not change with age. Conversely, some genes modulated by age were also modulated by melatonin treatment. In general melatonin treatment drove the expression levels of these genes closer to the expression levels detected in the younger animals. Notably, the abundance of lipocalin 2 (Lcn2) mRNA increased with age and was decreased in old animals treated with melatonin. Lcn2 is a member of the acute phase response family of proteins and its mRNA levels in the brain increase in response to inflammation. Many of the genes with expression reduced by melatonin are involved in inflammation and the immune system. This suggests that melatonin treatment may influence the inflammatory responses of old animals, driving them to resemble more closely those occurring in young animals.

Section: Introductionmentioning

confidence: 99%

Effects of melatonin and age on gene expression in mouse CNS using microarray analysis

Bondy

Neurochemistry International

et al. 2007

“…Мелатонин подавляет также апоптоз тимо-цитов (Pappolla et al, 1997;Provinciali et al, 1996). В ряде экспериментов показано, что введение мелатонина замедляет процессы старения и про-длевает жизнь модельным животным, например, мышам (Pierpaoli et al, 1994), крысам (Oakninbendahan et al, 1995) В данной работе мы исходили из предположения, что определяю-щим фактором влияния светового режима на продолжительность жизни D. melanogaster является изменение уровня метаболизма (Sheeba et al, 2002), приводящее к интенсификации генерации свободных радикалов и повреждений ДНК. Для проверки этого предположения нами выбрана ли-ния мух, характеризующаяся нарушением детоксификации активных форм кислорода (Sod) и линия мух, несущих мутацию гена, кодирующего фермент эксцизионной репарации ДНК (mus210).…”

unclassified

Melatonin influence on Drosophila melanogaster life span at different light regimes

Moskalev

Krementsova

Malysheva

2008

Ecological genetics

It was investigated the combined effects of different light regimes (round-the-clock lighting or darkening) and antioxidant melatonin on Drosophila melanogaster life span of wild type strain Canton-S,mutant strain with defect of red-ox system (Sod) and mu tant strain with disturbance of excision DNA repair (mus210). It was revealed, that maintenance of Drosophila imago at round-the-clock lighting leads to decrease of mean and/or maximum life span with compare to being at darkening. Adding of melatonin to Drosophila meal induces the geroprotector effects, mainly, in dark conditions. The effects mentioned above were most expressed in strain with mutation of Sod. All effects have revealed in both sexes. The data analysis has shown that mechanisms of different light regimes and melatonin influ ence on life span are rather different.

“…Few underpowered trials suggest that melatonin may enhance tumor response during treatment of breast cancer 104 . Melatonin supplementation during chemotherapy holds potential for reducing doselimiting toxicities 105 .…”

Section: Resultsmentioning

confidence: 99%

Untitled

2013

IJPSR

ABSTRACT:Introduction: Melatonin is a neuro-hormone secreted from the pineal gland and involved in various regulatory activities in body. Ever-increasing use of melatonin supplements and enlarging research evidences make the authors undertook the review to arrive at a qualitative conclusion whether melatonin supplements can act as potential treatment options or not. Methodology: A comprehensive search was undertaken in different electronic databases using various search terms. A total of 225 studies were identified including clinical research studies and basic experiments. Data were extracted individually from the studies and compiled in the end. Results: Melatonin has been used successfully in chronic insomnia and as an anti-oxidant in cancer and other age-related neuro-degenerative disorders, especially Alzheimer's disease and Autistic disorders. Its evidences of use in other conditions remained insufficient and inconclusive. Conclusion: Melatonin therapy may be considered as efficacious and safe in insomnia and as an anti-oxidant; however, other roles needs to be evaluated in further studies.